SCHEMBL3956808

SCHEMBL3956808

NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(N)c(Br)c1)NC(=O)N1CCC(n2cc(-c3ccccc3)[nH]c2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1

nearest known ligand 0.92

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 20/20 0.92
RAMP1 O60894 8/20 0.71
CALCA P06881 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3960179 0.96 CALCRL (1.00) CALCRLRAMP1CALCA
SCHEMBL3959483 0.91 CALCRL (0.76) CALCRLRAMP1CALCA
SCHEMBL3960639 0.88 CALCRL (0.72) CALCRLRAMP1CALCA
SCHEMBL3960339 0.88 CALCRL (0.85) CALCRLRAMP1CALCA
SCHEMBL6686441 0.88 CALCRL (0.85) CALCRLRAMP1CALCA
SCHEMBL7830129 0.87 CALCRL (0.92) CALCRLRAMP1CALCA
SCHEMBL3962596 0.86 CALCRL (0.82) CALCRLRAMP1CALCA
SCHEMBL3959794 0.86 CALCRL (0.68) CALCRLRAMP1CALCA
SCHEMBL3957693 0.85 CALCRL (0.67) CALCRLRAMP1CALCA
SCHEMBL3960305 0.84 CALCRL (0.66) CALCRLRAMP1CALCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498325-B2 Modified amino acids, pharmaceuticals containing these compounds and method for their production KARL THOMAS GMBH (DE) 2009-03-03 US claimed
EP-1440976-B1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production BOEHRINGER INGELHEIM PHARMA (DE) 2008-07-23 EP claimed
EP-1517674-B1 PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION BOEHRINGER INGELHEIM PHARMA (DE) 2007-04-11 EP claimed
EP-1769790-A1 Preparations for the intranasal application of selected CGRP antagonists derived from amino acids Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-04-04 EP claimed
US-20060193786-A1 Pharmaceutical composition for intranasal administration containing a CGRP antagonist BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US claimed
US-20050233980-A1 CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US claimed
EP-1207884-B1 USE OF CGRP ANTAGONISTS AND CGRP RELEASE INHIBITORS FOR CONTROLLING MENOPAUSAL HOT FLASHES BOEHRINGER INGELHEIM PHARMA (DE) 2004-11-03 EP claimed
US-20040076587-A1 Pharmaceutical composition for intranasal administration containing a CGRP antagonist BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-22 US claimed
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US disclosed
US-7498325-B2 Modified amino acids, pharmaceuticals containing these compounds and method for their production KARL THOMAS GMBH (DE) 2009-03-03 US disclosed
EP-1440976-B1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production BOEHRINGER INGELHEIM PHARMA (DE) 2008-07-23 EP disclosed
EP-1517674-B1 PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION BOEHRINGER INGELHEIM PHARMA (DE) 2007-04-11 EP disclosed
EP-1769790-A1 Preparations for the intranasal application of selected CGRP antagonists derived from amino acids Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-04-04 EP disclosed
US-20060193786-A1 Pharmaceutical composition for intranasal administration containing a CGRP antagonist BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2004-10-28 US disclosed
EP-1440976-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-07-28 EP disclosed
US-20040076587-A1 Pharmaceutical composition for intranasal administration containing a CGRP antagonist BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-22 US disclosed
WO-2004000289-A2 PREPARATIONS FOR THE INTRANASAL APPLICATION OF SELECTED CGRP ANTAGONISTS DERIVED FROM AMINO ACIDS AND A METHOD FOR THEIR PRODUCTION BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-12-31 WO disclosed
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2003-04-10 US disclosed
US-6344449-B1 HEADACHE AND MORPHINE DEPENDENCE DR. KARL THOMAE GMBH (DE) 2002-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS CALCRL 255/4885RAMP1 354/4885CALCA 544/4885
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 CALCRL 276/4885RAMP1 434/4885CALCA 463/4885
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production SLC1A5, NEFM, SRMS CALCRL 364/4885RAMP1 459/4885CALCA 536/4885
US-20050233980-A1 CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine SLC6A4, SLC6A2, HTR3B CALCRL 26/4885RAMP1 143/4885CALCA 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.